[ad_1]
Paris – Truvada, a preventive anti-HIV treatment manufactured by the American Gilead, is insufficiently used in France by homobaduals and people born in countries of sub-Saharan Africa, which constitute the majority of people infected every year in France, according to a report of Igas made public Monday.
This means of prevention called pre-exposure prophylaxis (Prep) is the subject of a poster campaign by the badociation Aides.
This mission report by the inspectors Gilles Duhamel and Aquilino Morelle of the General Inspectorate of Social Affairs (Igas), revealed by the daily newspaper Le Monde, points out a period of instruction of the temporary recommendation of use (RTU) of the Truvada " unusually long ".
A delay which resulted in " contaminations that could have been avoided " which would be " about 350 taking into account a progressive increase in load of the device ", Igas said in a statement.
" Conversely, the provision of the Truvada " via the temporary recommendation (RTU) " allowed France to earn 7.5 months compared to the authorization European Marketing Authorization (AMM) and avoid between 600 and 1,500 HIV infections "adds Igas.
Igas, " in spite of the very documented and circumstantial character of this report ", judge " regretful the virulent tone sometimes used by its authors as well as certain excessive remarks " while remaining " strongly committed to the transparency of its work and the independence of its inspectors ".
The implementation of the temporary recommendation of the preventive Truvada " proceeded satisfactorily ". This temporary recommendation ended on March 1, 2017, with the extension of the marketing authorization for this product for prevention.
However, the inspectors stress "a double inequality in access to treatment: territorial inequality (for the benefit of metropolitan urban areas) and insufficient recourse among men who have bad with men (MSM) and those born in heavily affected countries, mainly from sub-Saharan Africa, which constitute the vast majority of some 6,000 new infections each year
– " Accumulated delay " –
" Attention Special mention should be made of the extremely worrying situation in Guyana "they add.
The implementation of this prep preventive measure took place three years after the badociation Aides had seized the Medicines Agency (ANSM), and three and a half years after the authorization of this preventive treatment in the United States, which took place on July 16, 2012.
The inspectors are s scenarios evoking the number of contaminations avoided thanks to the advance of France in Europe or on the contrary " several hundred " or several thousand that could have been avoided if the process of decision had been faster.
They thus evoke " a number of contaminations consecutive to the accumulated delay " then being " between 1.666 and 4.000 ". An estimate based on a hypothesis – of which they did not have the possibility to verify the fundamentals ", they specify – of the general direction of the health which estimated that" the number of Contaminations avoided (thanks to the Prep) would potentially be 1,000 to 2,400 per year ".
" France was the first country in Europe to effectively allow, from January 2016, the use of Truvada as a preventive measure ," said AFP Dr. Dominique Martin, director general of the Agence du médicament.
" This (last) evaluation of the Igas is an absurd paradox compared to the reality, since one intervened before the other European countries ", he is indignant.
In fact, " the Prep is still little used – by only 6% of the people concerned, according to the data we have " he says, noting that the estimates of the 2015 DGS are " superior to what we observe today ".
Source link
